Search PubMed⌕ Search

PubMed · 3671236

Fatal hyperparathyroid crisis.

Abstract

A case of hyperparathyroid crisis presenting with a serum calcium level of 7.6 mmol/l is presented. The rarity and importance of recognizing the condition early is emphasized.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C A Keeling, M J Abrahamson, D G Harloe. 1987. Fatal hyperparathyroid crisis.. https://doi.org/10.1136/pgmj.63.736.111

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas.

The high mobility group As (HMGAs) belong to a family of nonhistone nuclear proteins that orchestrate the assembly of nucleoprotein complexes. Through a complex network of protein-DNA and protein-protein interaction, they play important roles in gene transcription, recombination, and chromatin structure. This protein family is involved, through different mechanisms, in both benign and malignant neoplasias. We have recently reported that transgenic mice carrying the Hmga1 or Hmga2 genes under transcriptional control of the cytomegalovirus promoter develop pituitary adenomas secreting prolactin and growth hormone. We have shown that the mechanism of the HMGA2-induced pituitary adenoma is based on the increased E2F1 activity. The expression profile of mouse normal pituitary glands and adenomas induced in HMGA transgenic mice revealed an increased expression of the ccnb2 gene, coding for the cyclin B2 protein, in the neoplastic tissues compared with the normal pituitary gland. Here, we show, by electrophoretic mobility shift assay and chromatin immunoprecipitation, a direct binding of HMGA proteins to the promoter of ccnb2 gene, whereas luciferase assays showed that HMGAs are able to up-regulate ccnb2 promoter activity. Finally, we report an increased CCNB2 expression in human pituitary adenomas of different histotypes that is directly correlated with HMGA1 and HMGA2 expression. Because cyclin B2 is involved in the regulation of the cell cycle, these results taken together indicate that HMGA-induced cyclin B2 overexpression gives an important contribution to experimental and human pituitary tumorigenesis.

Adenoma↗

A possible association between ionizing radiation and pituitary adenoma: a descriptive study.

BACKGROUND: Despite the recognition of ionizing radiation as a causal risk factor for a variety of solid tumors (including brain tumors), to date, such an association with pituitary adenoma (PA) has not been demonstrated. METHODS: To evaluate a possible association between past exposure to radiation and the occurrence of PA, the authors reviewed about 4900 medical records of patients who had been irradiated in childhood for tinea capitis. An additional search for patients was performed using the Israel Cancer Registry. The average radiation dose to the pituitary gland was estimated as 0.56 grays, and, for all patients, a meticulous validation of the irradiation was performed. RESULTS: A group of 16 patients who developed symptomatic PA after childhood exposure to radiotherapy were identified. Overall, the clinical and demographic characteristics of these patients were similar to other series reported in the literature. There was an apparently high rate of second primary tumors (25%), all of them in the irradiated area, diagnosed among this group. The methodologic issues that limit the demonstration of a possible association between radiation and PA and the epidemiologic and experimental findings in the literature are discussed. CONCLUSIONS: In view of the ample amount of evidence identifying low-dose ionizing radiation as a risk factor for a number of intracranial tumors as well as for tumors arising in endocrine organs, a radiation immunity of the pituitary gland is difficult to accept. Hence, the authors suggest that this series should be considered as preliminary observation that supports the role of ionizing radiation in the development of this tumor.

Adenoma↗

[Management of prolactinomas during pregnancy].

OBJECTIVE: To evaluate the safety of discontinuing drugs for prolactinoma during pregnancy, and the effect of prolactinoma on pregnancy. METHODS: Thirty-two cases of prolactinoma in pregnancy were enrolled, 22 microadenoma and 10 macroadenoma. RESULTS: Adenoma growing appeared in 6 cases. Among them 5 were macroadenoma, dopamine agonists were then reused and surgery were carried out in 2 of them. The other was one microadenoma, dopamine agonists was reinstituted. No side effect on fetus's weight and appearance was seen. Gestation complication was as normal. CONCLUSIONS: Discontinuing dopamine agonists is safe during pregnancy for microadenoma. The risk of macroadenoma enlargement during pregnancy is high. Regular visal field testing is necessary during pregnancy. Prolactinoma doesn't influence gestation complication and fetus.

Adenoma↗